Key points are not available for this paper at this time.
Objective: The aim of this 12-week, blind randomized control comparative study was to determine the safety and efcacy of uvoxamine and clomipramine in adult outpatients with obsessive-compulsive disorder (OCD). Method: 156 adult outpatients with DSM-IV OCD were randomly assigned into two groups to receive 100 to 300 mg of uvoxamine CR (N=78) or Clomipramine (N = 78) once daily at bedtime for 12 weeks. Intentto-treat, analysis of efcacy assessments with the Yale- Brown Obsessive Compulsive Scale (YBOCS), Clinical Global Impressions-Severity of Illness scale (CGI-S) was done. Results: The percentage of responders (response >35% improvement in the YBOCS total score) at the end of the study was similar in both groups (62% FLV vs 65% CMI) by LOCF analysis. Fluvoxamine CR and Clomipramine showed a signicant (>35%) decrease in YBOCS total score beginning at week 2. This early response was sustained at all subsequent visits. At endpoint, there was a mean decrease of 11.65 ± 0.7 (44.89%) in the YBOCS total score compared with baseline in the uvoxamine CR treatment group versus a mean decrease of 12.3 ± 0.7 (46.32%) in the clomipramine treatment group (p = .001). It was observed that FLV was better tolerated than CMI among subjects; patients treated with CMI had more anticholinergic side effects (dry mouth, constipation, and tremor) and premature withdrawals due to adverse events. CGI-S scores also showed a statistically signicant improvement of 59.25% in FLV group and 55.14% in CMI group. Conclusion: The study show that both uvoxamine and clomipramine has equivalent efcacy, wherein both the drugs start showing signicant reduction in primary efcacy parameters: YBOCS and CSI-S scores since the end of second week. Treatment dropout rate was higher in the Clomipramine (24%) group than the uvoxamine (17%) group. We concluded that with long-term or even life- long treatment appearing necessary for people with OCD, Fluvoxamine would appear to be the treatment of choice in view of their tolerability and safety advantages compared with clomipramine.
Anirudh Atul Salunke (Wed,) studied this question.